New Agents and Emerging Strategies in Advanced Breast Cancer: Patient-Centric Navigation in the Age of Personalized Care

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Merck & Co.

Description:
Breast Cancer is the most common cancer found in women, regardless of race or ethnicity with incidence in the United States being 1 in 8 (about 12 percent). Although death rates have been steadily decreasing over the past 20 years, cure becomes less likely in patients with distant metastases. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (mBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Therapy for advanced breast cancer is increasingly personalized, thanks to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents have been recently introduced or are in development, including PARP inhibitors. The complexities of today’s more personalized care pose multiple challenges to effective clinical and economic management of the disease.

Upon completion of this activity, participants will be able to:

  • Analyze the mechanisms of action of new and emerging targeted therapies, including PARP inhibitors, for the treatment of advanced breast cancer

  • Describe the impact of BRCA1/2 testing on clinical outcomes for patients with advanced breast cancer

  • Evaluate the latest clinical trial data of PARP inhibitors in patients with advanced breast cancer

  • Anticipate and manage toxicities that may occur with the use of new agents in advanced breast cancer, including PARP inhibitors

  • Examine patient-centric navigation through the complex pathways required in the increasingly personalized care of advanced breast cancer

  • Discuss methods to enable optimal cost management of potential PARP inhibitors to be realized by multiple breast cancer stakeholders including managed care organizations
     

Faculty: Lajos Pusztai, MD, DPhil
Professor of Medicine
Director, Breast Cancer Translational Research
Co-Director, Yale Cancer Center Genetics and Genomics Program
Yale Cancer Center
Yale School of Medicine

Disclosure:

Dr. Pusztai serves on an advisory board for AstraZeneca, Merck and Seattle Genetics. He has received research/grant support from AstraZeneca, Merck and Seattle Genetics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue